Download Files:
Hydroxychloroquine (sulfate)
$60 – $135
Products Details
Product Description
– Hydroxychloroquine sulfate (HCQ sulfate) is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine sulfate is efficiently inhibits SARS-CoV-2 infection in vitro[1][2][3].
Web ID
– HY-B1370
Storage Temperature
– 4°C (Powder, sealed storage, away from moisture and light)
Shipping
– Room Temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C18H28ClN3O5S
Citations
– ACS Appl Mater Interfaces. 2022 Oct 27.|Acta Pharm Sin B. 2021 Dec;11(12):3966-3982.|Acta Pharmacol Sin. 2022 Oct 25.|Autophagy. 2022 Oct 27.|Biochem Pharmacol. 2021 Dec 28;114904.|BMC Med. 2021 Oct 15;19(1):247.|Cell Death Dis. 2020 Apr 24;11(4):279.|Cell Discov. 2020 Mar 18;6:16.|Cell Rep. 2021 Apr 6;35(1):108959.|Cell Signal. 2019 Feb;54:17-26. |Clin Chem. 2019 Dec;65(12):1522-1531. |Clin Sci (Lond). 2019 Aug 14;133(15):1759-1777.|Eur J Pharmacol. 2 September 2022, 175237.|Front Bioeng Biotechnol. 2020 May 8;8:378.|Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Transmissores de Hematozoários. 2020 Sep.|Heliyon. 2023 Oct 31.|iScience. 30 June 2022, 104690.|J Autoimmun. 2019 May;99:39-47.|J Biol Chem. 2023 May 11;104814.|J Control Release. 2020 Jan 28;320:304-313.|Life Sci. 2020 Apr 1;246:117366.|Life Sci. 2020 Feb 15;243:117277.|Life Sci. 2021 Oct 26;120095.|Nat Biomed Eng. 2021 Nov 8.|Nat Commun. 2021 Aug 16;12(1):4964.|Nucleic Acids Res. 2021 Jan 8;49(D1):D1113-D1121.|Pharmacol Res. 2021 Apr 30;169:105642.|Phytomedicine. 2021, 153465.|Research Square Preprint. 2021 Oct.|Sci Rep. 2022 Oct 29;12(1):18259.|STAR Protoc. 2022, 3(4): 101859.|Theranostics. 2020 Apr 27;10(13):5829-5844. |Acta Pharmacol Sin. 2021 Feb 19.|Aging. 2021 Mar 10;13(6):8421-8439.|Am J Cancer Res. 2020 Nov 1;10(11):3896-3910.|Arthritis Rheumatol. 2022 Sep 3.|Autophagy. 2021 Sep 15;1-19.|Autophagy. 2022 Aug 29.|Autophagy. 2022 Jan 6;1-20.|Biochem Biophys Res Commun. 2 March 2022.|Biochem Biophys Res Commun. 2020 Dec 10;533(3):474-480.|Br J Pharmacol. 2023 Feb 14.|Cell Biochem Funct. 2022 Apr 29.|Curr Med. 2023 Oct 17.|iScience. 30 June 2022, 104690.|J Exp Pharmacol. 2022 Nov 8;14:353-365|Nat Biotechnol. 2022 Dec;40(12):1834-1844.|Nat Commun. 2022 Jun 14;13(1):3419.|Patent. US20230218606A1.|Research Square Preprint. 2023 Sep 6.|Virology. 2023 Jul 24.
References
– [1]Manzo C, et al. Psychomotor Agitation Following Treatment with Hydroxychloroquine. Drug Saf Case Rep. 2017 Dec;4(1):6.|[2]Lamphier M, et al. Novel small molecule inhibitors of TLR7 and TLR9: mechanism of action and efficacy in vivo. Mol Pharmacol. 2014 Mar;85(3):429-40.|[3]Yao X, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Mar 9. pii: ciaa237.
CAS Number
– 747-36-4
Molecular Weight
– 433.95
Compound Purity
– 99.99
SMILES
– CCN(CCO)CCCC(NC1=CC=NC2=CC(Cl)=CC=C12)C.O=S(O)(O)=O
Clinical Information
– Launched
Research Area
– Cancer; Infection
Solubility
– DMF : 1.4 mg/mL (ultrasonic)|DMSO : < 1 mg/mL (ultrasonic)|H2O : 110 mg/mL (ultrasonic;warming)
Target
– Autophagy;Parasite;SARS-CoV;Toll-like Receptor (TLR)
Isoform
– Plasmodium;TLR7;TLR9
Pathway
– Anti-infection;Autophagy;Immunology/Inflammation
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
